Search Results

Business

Biocare Medical and Molecular Instruments Partner to Revolutionize Automated Bioimaging Through ONCORE Pro X and HCR™ RNA-ISH Assays

Biocare Medical, a leader in fully open automated instrumentation, announces a collaboration with Molecular Instruments® (MI), the inventor of the HCR™ Imaging technology.

January 5, 2024

·

3 min read

OncoRes Medical’s Imaging System for Breast Cancer Surgery Gains FDA Breakthrough Device Designation

OncoRes Medical has received a Breakthrough Device designation from the U.S. Food and Drug Administration to expedite development of its Quantitative Micro-Elastography (QME) Imaging System

May 5, 2021

·

5 min read

Biotech Bay

Biocare Medical Unveils ONCORE Pro, a Fully Automated IVD Benchtop Platform for Immunohistochemistry and In-situ Hybridization

Biocare Medical, LLC, a leading provider of innovative immunohistochemistry (IHC) instrumentation and reagents, announces the release of the fully automated staining platform ONCORE Pro™ for IHC and ISH applications.

January 5, 2021

·

3 min read

Genetown

Oncore Pharma Signs a Multi-Year Agreement Valued at $61.8 Million

Oncore Pharma Inc., a life sciences company specializing in blood-based biomarker tests for early cancer detection, announced today that it has signed a multi-year agreement with BodyCheck NL valued at $61.8 million.

October 10, 2019

·

2 min read

FDA

Pillar Biosciences oncoReveal™ CDx pan-cancer solid tumor IVD now FDA approved for general tumor profiling on the Illumina MiSeq™ Dx System

Pillar Biosciences, Inc., the leader in Decision Medicine™ today announced that the U.S. Food and Drug Administration (FDA) has approved the company’s Premarket Approval (PMA) supplement application for its oncoReveal™ CDx pan-cancer solid tumor in vitro diagnostic (IVD).

April 23, 2024

·

3 min read

Ascelia Pharma Successfully Meets Primary Endpoint with Strong Headline Results in Orviglance Phase 3 Study

The pivotal Phase 3 study, SPARKLE, successfully met the primary endpoint and demonstrated that the company’s magnetic resonance imaging (MRI) contrast agent

May 2, 2024

·

6 min read

Drug Development

OncoResponse Announces Initiation of Phase 1/2 Clinical Trial of OR502, anti-LILRB2 Antibody, in Subjects with Advanced Cancer

OncoResponse today announced the dosing of the first participant in the Phase 1/2 trial of OR502, a novel, humanized anti-leukocyte immunoglobulin like receptor B2 (LILRB2) antibody that rescues innate and adaptive immune responses from LILRB2 mediated immune suppression.

November 29, 2023

·

3 min read

Genetown

4D Path Announces New Data Highlighting Efficacy of the Q-Plasia OncoReader (QPOR™) Platform

4D Path is pleased to announce today new clinical data highlighted in two abstracts at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 – June 4, 2024 at McCormick Place, Chicago.

May 30, 2024

·

4 min read

Genetown

Pillar Biosciences Launches oncoReveal™ Core LBx, an NGS Kit to Enable Localized Liquid Biopsy Testing

Pillar Biosciences, Inc., the leader in Decision Medicine™, has announced the global launch of oncoReveal ™ Core LBx, a research-use-only (RUO) next-generation sequencing (NGS) kit designed to enable laboratories with a solution for liquid biopsy-based pan-cancer tumor profiling.

September 19, 2023

·

3 min read

Business

OncoResponse Announces Appointment of Carol Gallagher to Board of Directors

OncoResponse, a clinical-stage biotech company advancing immunotherapies derived from the immune systems of Elite Cancer Responders, announced the appointment of Carol Gallagher, Pharm.D., as an Independent Director to its Board of Directors.

September 6, 2023

·

2 min read